Understanding and Improving Platinum Anticancer Drugs - Phenanthriplatin
Approximately half of all patients who receive anticancer chemotherapy are treated with a platinum drug. Despite the widespread use of these drugs, the only cure that can be claimed is that of testicular cancer following cisplatin treatment. This article reviews some of our recent work on phenanthri...
Main Authors: | Johnstone, Timothy (Contributor), Park, Ga Young (Contributor), Lippard, Stephen J. (Contributor) |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemistry (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor) |
Format: | Article |
Language: | English |
Published: |
The International Institute of Anticancer Research,
2015-02-24T20:39:57Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Nucleotide Binding Preference of the Monofunctional Platinum Anticancer-Agent Phenanthriplatin
by: Riddell, Imogen Anne, et al.
Published: (2016) -
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile
by: Park, Ga Young, et al.
Published: (2013) -
The Chiral Potential of Phenanthriplatin and Its Influence on Guanine Binding
by: Lippard, Stephen J., et al.
Published: (2015) -
Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage
by: Gregory, Mark T., et al.
Published: (2015) -
Comparison of phenanthriplatin, a novel monofunctional platinum based anticancer drug candidate, with cisplatin, a classic bifunctional anticancer drug
by: Li, Meiyi, S.M. Massachusetts Institute of Technology
Published: (2013)